Tìm theo
MGI-114
Thuốc Gốc
Small Molecule
CTHH: C15H18O3
PTK: 246.3016
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C15H18O3
Phân tử khối
246.3016
Monoisotopic mass
246.125594442
InChI
InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
InChI Key
InChIKey=NICJCIQSJJKZAH-AWEZNQCLSA-N
IUPAC Name
(6'R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-6',7'-dihydrospiro[cyclopropane-1,5'-indene]-7'-one
Traditional IUPAC Name
irofulven
SMILES
CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1
Độ hòa tan
5.20e-01 g/l
logP
0.67
logS
-2.7
pKa (strongest acidic)
12.77
pKa (Strongest Basic)
-1.7
PSA
57.53 Å2
Refractivity
70.91 m3·mol-1
Polarizability
27.33 Å3
Rotatable Bond Count
1
H Bond Acceptor Count
3
H Bond Donor Count
2
Physiological Charge
0
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Cơ Chế Tác Dụng : A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells. Once inside the cells, the compound binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or “cell suicide.” During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised.
Chỉ Định : Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Irofulven
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB05786
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=148189
ChemSpider
http://www.chemspider.com/Chemical-Structure.130640.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50092217
Wikipedia
http://en.wikipedia.org/wiki/Irofulven
... loading
... loading